Anecortave (rINN) /ænəˈkɔːrteɪv/ is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration.

Although similar in chemical structure to the corticosteroid hydrocortisone acetate, it possesses no glucocorticoid activity.

[2] Retaane (15 mg anecortave acetate depot suspension) which is manufactured by Alcon, Inc., was a fast track designated product which was also a drug in FDA’s Pilot Continuous Marketing Application (CMA) program which often enrolls drugs which are being brought to the market and have an indication for a significant unmet medical need.

This allowed Retaane to file with the FDA using a “rolling” New Drug Application, which allows specific units, Chemistry, Manufacturing, and Controls (CMC), pre-clinical, and the clinical unit, of the NDA to be reviewed as they are completed instead of as one large document.

[6] In 2009, Alcon announced the end of the drug's development for reducing intraocular pressure associated with glaucoma.